Open response to Abbott Laboratories letter to MSF of March 15

March 15, 2006

Miles White Chairman and CEO Abbott Laboratories 100 Abbott Park Road Abbott Park, IL 60064

Dear Mr. White,

We are writing to you to express our concern about the lack of availability in developing countries of the new melt extrusion (Meltrex) formulation of lopinavir/ritonavir (LPV/r), marketed as Kaletra (200/50mg tablets).

LPV/r has been recognized as an essential medicine by the WHO and will be included in its revised antiretroviral treatment guidelines , in which boosted protease inhibitors represent the cornerstone of second-line therapy. As you know, the tablet formulation of LPV/r, approved by the US Food and Drug Administration in October 2005, has critically important advantages for patients in developing countries: no dietary restrictions, lower pill burden, and most importantly, storage without refrigeration.

Due to the storage requirements of the old formulation, there is the risk that some patients in tropical climates are currently using degraded LPV/r capsules. In short, there is an urgent need in developing countries for access to the new heat-stable formulation of LPV/r, as no other boosted protease inhibitors are practical to use in the hot climates of many of these countries.

We urge Abbott to take the following actions to make this crucial second-line option accessible in developing countries:

1. Immediately file for registration of the new LPV/r formulation in all countries where the old formulation was registered or pending, as well as in other developing countries.

According to the WHO/AMDS registration database published in October 2005, the old formulation of LPV/r (133/33.3 mg soft gel capsules) is registered in 55 countries and registration is pending in 13 others, covering 68 of the 69 countries eligible in Abbott's Access Program. But the new formulation of the drug has not been registered in any country except for the US. We urge you to immediately file for registration of the new formulation of LPV/r (200/50mg tablets) in developing countries, so that the old formulation can be replaced by the new one, as was done in the US.

2. Communicate the countries and the filing dates where registration of the new formulation of LPV/r is pending and a timeline for submissions to remaining countries.

We ask that Abbott communicate the countries and the filing dates where registration of the new formulation of LPV/r is pending so that health advocates in these countries can work with national drug regulatory authorities to overcome any delays and provide a timeline for submitting remaining registration requests.

3. Publish a price for the new formulation of LPV/r for least-developed and middle-income countries.

Since May 2002, Abbott has been selling the old formulation of LPV/r in Africa and Least Developed Countries for $500 per patient per year on an FOB basis (freight, insurance, customs handling, taxes and duties paid by purchaser). Abbott has not yet made public any price for the new formulation of LPV/r in developing countries. We ask that Abbott establish a price that is at least as low as the price for the old formulation in least-developed countries.

Abbott's Access Program for the old formulation of LPV/r excludes middle-income countries, resulting in prices up to 12 times more than in least-developed African countries. We urge you to make the new formulation available at an affordable price in middle-income countries where millions live on less than US $2 per day.

4. Develop a heat-stable formulation of RTV and make it accessible in developing countries.

A separate, heat-stable formulation of ritonavir (RTV), marketed as Norvir, is also needed in developing countries so that care-providers can implement the forthcoming WHO guidelines and pair RTV with other available and affordable, heat-stable protease-inhibitors.

5. Develop a pediatric formulation of the new formulation of LPV/r.

WHO draft pediatric guidelines recommend LPV/r for use in children if there is cold-chain access. While this new formulation overcomes the storage challenges presented by the old formulation, care-providers would not be able to cut or crush tablets because the new LPV/r is a coated tablet. Therefore, care-providers need a pediatric version of this formulation so that they can provide adequate second-line regimens for children as well as adults.

6. Work with countries to make the new formulation of LPV/r easily available while registration applications are being considered.

Because the drug registration process can take months if not years to complete, we ask that Abbott establish a reliable interim system to distribute this new formulation to treatment programs in developing countries while registration is pending.

Sincerely,

  • Stephen Lewis, United Nations Secretary General's Special Envoy for HIV/AIDS in Africa
  • Craig McClure, Executive Director, The International AIDS Society
  • Médecins Sans Frontières / Doctors Without Borders (MSF)
  • European AIDS Treatment Group
  • American Academy of HIV Medicine (AAHIVM), USA
  • AIDS Treatment Activist Coalition (ATAC), USA
  • The Drug Development Committee of AIDS Treatment Activist Coalition (ATAC), USA
  • Elaine J. Abrams, MD, Professor of Pediatrics & Epidemiology, Director, MTCT-Plus, International Center of AIDS Care and Treatment Programs,
  • Mailman School of Public Health, Columbia University, USA
  • Lisa Hirschhorn MD MPH, Associate Director, Office of International Programs,
  • Harvard Medical School Division of AIDS, USA
  • Joia S. Mukherjee, MD, MPH, Medical Director, Partners In Health, USA
  • David Hoos, MD, MPH , Director Multicountry Antiretroviral Program (MCAP)
  • Mailman School of Public Health, Columbia University, USA
  • Wafaa El-Sadr, MD, MPH, Columbia University, USA
  • Mark Mirochnick, MD, Associate Professor of Pediatrics, Boston University School of Medicine, USA
  • Ruby Faysey, MD, MPH, Pediatric Clinical Advisor, ICAP, Columbia University School of Public Health, USA
  • Kevin Outterson, Associate Professor of Law, West Virginia University, USA
  • David Scondras, President, Search for a Cure, USA
  • Foundation for Integrative AIDS Research (FIAR), USA
  • Gay Men's Health Crisis (GMHC), USA
  • Global AIDS Alliance, USA
  • The Center for AIDS Information & Advocacy, USA
  • Treatment Action Group (TAG), USA
  • Student Global AIDS Campaign, USA
  • Health Global Access Project (GAP), USA
  • Iglesia Evangelica Luterana Unida en Argentina y Uruguay, Pasotral Ecumenica, VIH-SIDA,
  • Coordinador Regional Plan de Accion en VIH-SIDA de la Federacion Luterana Mundial,
  • Argentina
  • Brian Haill, President, The Australian AIDS Fund Incorporated, Australia
  • Gottfried Mernyi, Managing Director, Protestant Association for World Mission, Austria
  • Sonja Hauser, Assoc. AIDS Life, Production, Austria
  • Anton Mair, Head of Dept. for Evaluation, Development Policy and Strategies, Federal Ministry of Foreign Affairs, Austria
  • Birgit Habermann, Coordinating Committee for Development Issues (KEF) at the Academy of Sciences, Austria
  • Dr. Florian Breitenecker, General Practioner, Detention Centre Josefstadt, Austria
  • Stephan Neuhäuser, International Research Cooperation, Federal Ministry for Education, Science and Culture, Austria
  • Dr. Norbert Kohrgruber (MD), Medical University of Vienna, Dept. of Dermatology, Austria
  • Dr. Angela Ã-llinger, Dermatologist/Spezialist HIV/Aids, General Hospital Linz (AKH), Austria
  • Dr. Harald Schopper, Head of the Detention Centre Josefstadt, Austria
  • Univ. Prof. Dr. Christoph Wenisch, President of the Austrian Society of Infectious Diseases, Kaiser Franz Josef Hospital, Austria
  • Dr. N. Vetter, Head of the Lung Dept. Otto-Wagner Hospital, Austria
  • Dr. Andrea Steuer, Otto-Wagner Hospital, Austria
  • Dr. Brigitte Schmied, Otto-Wagner Hospital, Austria
  • Dr. Wolfgang Steflitsch, Otto-Wagner Hospital, Austria
  • Dr. Heinrich Haber, Otto-Wagner Hospital, Austria
  • Dr. Manfred Gartner, Otto-Wagner Hospital, Austria
  • Dr. Gunvor Koitz, Otto-Wagner Hospital, Austria
  • Dr. Herbert Keller, Otto-Wagner Hospital, Austria
  • Dr. Wolfgang Scholz, Otto-Wagner Hospital, Austria
  • Dr. Alexander Aichelburg, Otto-Wagner Hospital, Austria
  • Dirk Pyck, Directeur, Sensoa (Dutch speaking platform of AIDS NGOs), Belgium
  • Professor Robert Colebunders, Medical Tropical Institute, Antwerpen, Belgium
  • Mr. Thierry Martin, Director, Prevention SIDA, Belgium
  • GESTOS - Soropositividade, Comunicação e Gênero, Brazil
  • ABIA - Associação Brasileira Interdisciplinar de AIDS, Brazil
  • CONECTAS Direitos Humanos, Brazil
  • Grupo Pela Vidda São Paulo, Brazil
  • DAWN Brasil, Brazil
  • GAPA/São Paulo, Brazil
  • LACCASO - Consejo Latinoamericano y del Caribe de ONGs con Servicio en VIH/SIDA, Brazil
  • Canadian HIV/AIDS Legal Network, Canada
  • Interagency Coalition on AIDS and Development (ICAD), Canada
  • Canadian Harm Reduction Network, Canada
  • Dr. Noah Novogrodsky, Canada
  • Canadian AIDS Society, Canada
  • Dignitas International, Canada
  • Dr. Joel Lexchin, Associate Professor, School of Health Policy and Management, York University,
  • Canada
  • Yiming Shao, M.D., Ph.D., Chief Expert on AIDS, Chinese Center for Disease Control and Prevention (China CDC), National Center for AIDS/STD Control and Prevention (NCAIDS), China CDC, Director, Division of Research on Virology and Immunology, NCAIDS, Chairman, Committee on Virology, Chinese Society for Microbiology, China
  • Odilon Couzin, Executive Director, China AIDS Info, China
  • Nina Friss-Moleer, MD, PhD, Clinical Research Associate, Copenhaged HIV Programme, Hvidovre University Hospital, Denmark
  • Darío Abarca, Ecuadorian Coalition of PLWHA, Ecuador
  • Asociación Atlacat, El Salvador
  • Pr. Eric Delaporte, UMR 145 L'Institut de recherche pour le developpement (IRD)/ Université de Montpellier, France
  • Pr. Laurent Mandelbrot, Hôpital Louis Mourier, France
  • Pr. Jean-Michel Molina, Chef de Service, Maladies Infectieuses, Hôpital Saint Louis, France
  • Dr. Suna Balkan, Service de Maladies Infecieuses, Hôpital Saint Louis, France
  • Dr. Jean-Baptiste Guiard Schmidt, Service des Maladies Infecieuses et Tropicales, Hôpital Tenon, France
  • Pr. Patrick Yeni, Chef de Service, Maladies Infectieuses, Hôpital Bichat, France
  • Dr. François Bourdillon, Président de la Société de Santé Publique, France
  • Pr. François Dabis, Unité INSERM 593, Institut de Santé Publique, Epidémiologie et Développement (ISPED), France
  • Dr. Xavier Anglare, ISPED, France
  • Dr. Catherine Seyler, ISPED, France
  • Dr. Christine Danel, ISPED, France
  • Dr. Besigin Tonwe-Gold, ISPED, France
  • Dr. Valériane Leroy, ISPED, France
  • Dr. Elise Klement, Service de Maladies Infectieuses, Hôpital Pitié-Salpêtrière, France
  • Eric Fleutelot, Head of International Programs, Sidaction, France
  • TRT-5, France
  • Act Up-Toulouse, France
  • Albert Petersen, Chair of the Ecumenical Pharmaceutical Network Nairobi, Germany
  • Dr. med Günther Schmutz, Arzt für Innere Medizin, Haematologie und Internistische Onkologie, HIV-Schwerpunktpraxis, Germany
  • Dr. med. Stefan Esser, Leiter der HIV-Ambulanz am Universitatsklinikum Essen, Klinik für Dermatologie und Venerologie, Germany
  • Bernd Pastors, Managing Director and Member of the Board, German Medical Organization, Action Medeor, Germany
  • Prof. Dr. Schlomor Staszewski, HIVCENTER, Klinikum der Johann Wolfgang Goethe- Universität Frankfurt am Main Medizinische Klinik III, Germany
  • Dr. med. Tessa Lennemann, HIVCENTER Klinikum der Johann Wolfgang Goethe- Universität Frankfurt am Main Medizinische Klinik III, Germany
  • Dr. med. Heiko Jessen, HIV-Schwerpunktpraxis, Germany
  • Dr. med. Heribert Knechten, 1. Vorstandsvorsitzender, Deutsche Arbeitsgemeinschaft niedergelassener Ãâ??rzte in der Versorgung HIV-Infizierter e.V. (DAGNÃâ?? e.V.), Germany
  • Dr. med. Peter Hartmann, Arzt, Praxis mit HIV Schwerunkt, Germany
  • Netzwerk der Therapieaktivisten, c/o Projekt Information e.V., Germany
  • Dr. Luis Carlos Escobar Pinzón, Bundesgeschäftsführer, Deutsche AIDS-Hilfe e.V., Germany
  • Dr. med. Albrecht Ulmer, Gemeinschaftspraxis, Germany
  • Dr. med. Andreas Carganico, Facharzt für Allgemeinmedizin, Gemeinschaftspraxis, Germany
  • Dr. med. Ansgar Rieke, Arzt für Innere Medizin / Nephrologie / Infektiologie (DGI), Immunologische Ambulanz, II. Medizinische Klinik, Klinikum Kemperhof, Koblenz, Germany
  • Dr. med. Bernd Buchholz, HIV-Ambulanz der Universitätsklinik Mannheim, Germany
  • Dr. med. Christoph Mayr, Arzt, Praxis MVZ Ãâ??rzteforum Seestrasse, Germany
  • Dr. med. Gundula Notheis, Oberärztin und Leiterin der Immundefekt-Ambulanz, Germany
  • Dr. von Haunerschen Kinderspital, Germany
  • Dr. med. Hans Jäger, Gemeinschaftspraxis München, Germany
  • Dr. med. Holger Flick, DTMPH, Arzt, Medizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie Charité Universitätsmedizin, Germany
  • Dr. med. Jan-Peter Siedentopf, Infektionsambulanz, Klinik für Geburtsmedizin, Campus Virchow-Klinikum, Charité – Universitätsklinikum, Germany
  • Dr. med. Jörg Gölz, Praxiszentrum Kaiserdamm Berlin, Germany
  • Dr. med. Katharina von Weizsäcker, Infektionsambulanz, Klinik für Geburtsmedizin, Campus Virchow-Klinikum, Charité – Universitätsklinikum, Germany
  • Dr. Rainward Bastian, Director, German Institute for Medical Mission (DIfÃâ??M), Germany
  • Olaf Hirschmann, MPH, Advisor HIV/AIDS in Development Policy, Brot für die Welt, Diakonisches Werk der EKD, Germany
  • P.D. Dr. med. Keikawus Arastéh, Direktor der Klinik für Innere Medizin Infektiologie / Gastroenterologie, Vivantes Auguste-Viktoria-Klinikum, Germany
  • Prof. Dr. med. Gerd Fätkenheuer, Klinik I für Innere Medizin, Klinische Infektiologie Universitätsklinikum, Germany
  • Prof. Dr. med. Hartwig Klinker, Leiter des Schwerpunktes Infektiologie, Medizinische Klinik und Poliklinik II Klinikum der Universität, Germany
  • Prof. Dr. med. Jürgen Lohmeyer, Infektiologie-Ambulanz Universitätsklinikum, GieÃ?en, Germany
  • Prof. Dr. med. Norbert Suttorp, Director, Charité-Universitätsmedizin Berlin Department of, Infectious Diseases, Germany
  • Marwin Meier, Co-ordinator HIV and AIDS, World Vision Germany, Germany
  • Chrisoula Botsi, MD, ''Andreas Sigros'' Hospital, Greece
  • Hadjichristodoulou Christos,MD,PhD, Ass.Professor of Epidemiology and Infectious Diseases, Medical School of Larissa, University of Larissa, Greece
  • Antonios Vasiloyiannakopoulos ,MD,PhD, Head of 1st Infectious Diseases Department, ''Erricos Dunant'' Hospital, Vice President of the Hellenic Association of Tropical,Geographical and Travelling Medicine, Greece
  • Gatsiou Hariklea ,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Koutsouri Natassa,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Kirpoglou Panagiotis,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Amanatidou Konstantina,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Rapti Rena ,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Dimou Evangelini,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Kanelopoulos Petros,MD,PhD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Vassilopoulou Adamantia,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Palamarou Christina,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Sevastianos Vassilios,MD, Internal Medicine, ''Erricos Dunant'' Hospital, Greece
  • Peros Ioannis, MD,PhD, Dermatologist, ''Erricos Dunant'' Hospital, Greece
  • Hellenic Association of Tropical,Geographical and Travelling Medicine, Greece
  • ACT UP Hellas, Greece
  • Greek Committee of Feeding Minds,Fighting Hunger, Greece
  • Igisipolis,Club for Dialogue and Activism, Greece
  • Hellenic Branch of Feminist net, Greece
  • Antigoni: European Watch Against Racism and Xenophobia, Greece
  • Helen Choremi-Papadopoulou, MD, Ass. Professor of Athens University, Director of the Immunology-
  • Compatibility Department, General Hospital “Laiko”, Greece
  • Albert Adalsteinsson, HIV Group Iceland, Iceland
  • Italian League for Fighting AIDS (LILA), Italy
  • Action Aid International, Italy
  • Amref Italia, Italy
  • Anna Siniscalchi, Department of Medicine clinic, University of Ferrara, Italy
  • Dr. Daniele Dionisio, Director, Infectious Disease Division, Pistoia Hospital, and Coordinator, Áccess to
  • Drugs: International Policies” branch, CLIA, Italy
  • Persia , Iran
  • Gideaon Hirsh, MD, Executive Director, Israel AIDS Task Force, Israel
  • Naomi Wakasugi MD., PhD., Professor, Graduate School of Political Science, WASEDA University,
  • Japan
  • Takashi Sawada, MD, Vice Chair Person, Services for the Health in Asian African Regions (SHARE),
  • Japan
  • Aleksandrs Molokovskis, Board Chair, Association HIV. LV, Latvia
  • AGIHAS (PLWHA Support Group), Latvia
  • Marcel van Soest, Executive Director, World AIDS Campaign, The Netherlands
  • Bianca Kamps, Director IDA- HIV/AIDS Group, The Netherlands
  • Sjoera Dikkers,Director, Stop AIDS Now!, The Netherlands
  • Mauro Guarinieri, Global Network of People living with HIV/AIDS (GNP ), The Netherlands
  • Asociación Nicaraguense de Personas Vivendo con VIH y SIDA, Nicaragua
  • Asociación Lazos de Vida – Iquitos, Peru
  • Sipho Mthathi, General Secretary, Treatment Action Campaign, South Africa
  • Prof. Andy Gray, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa
  • Dr Douglas Wilson, Department of Medicine, Edendale Hospital, University of KwaZuluNatal, South Africa
  • Dr Andrew Boulle, Infectious Diseases Epidemiology unit, University of Cape Town, South Africa
  • Dr Elma de Vries, Rural Doctors Association of South Africa (RuDASA), South Africa
  • Artists for a New South Africa, South Africa
  • Robert Acquet, Service Comptabilité, Bayer Crop Science SA Lyon, Barcelona, Spain
  • Jose Gatell MD.Infectious Diseases and HIV Unit.Hospital Clinic Barcelona, Vice President European HIV Society, Spain
  • Carles Campuzano I Canades, Member of Parliament, Spain
  • Jose Javier Sanchez Espinosa, Red Cross, Spain
  • Tenemos SIDA, Spain
  • GobalSIDA, Spain
  • A MAS, Spain
  • Anesvad, Spain
  • Acción contra el SIDA, Spain
  • IAVI, Spain
  • Fundación Ecología y desarrollo, Spain
  • Fundación Triángulo, Spain
  • Más Madrid, Spain
  • RED 2002, Spain
  • Save the Children, Spain
  • World Aids Campaign, Spain
  • Farmamundi, Spain
  • Per Björkman, M.D. Ph.D, Dept. Of Infectious Diseases, Malmoe University Hospital, Sweden
  • Gerhard Bärtschi , CEO TearFund Switzerland, Switzerland
  • Ecumenical Advocacy Alliance, Switzerland
  • Praphan Phanuphak MD, Professor of Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University; and Deputy Director of HIV Netherlands Australia Thailand, Thai Red Cross AIDS Research Centre, Thailand
  • Kiat Ruxrungtham, M.D., Associate Professor of Medicine, Head, Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University; and Deputy Director of HIV Netherlands Australia Thailand, Thai Red Cross AIDS Research Centre, Thailand
  • Jintanat Ananworanich MD, Chief, South East Asia Research with Hawaii (SEARCH) Consultant, The HIV Netherlands, Australia, Thailand Research Collaboration (HIV-NAT), Thailand
  • Chris Duncombe MD, Senior Staff Physician, The HIV Netherlands, Australia, Thailand Research Collaboration (HIV-NAT), Thailand
  • Kulkanya Chokephaibulkit MD, Senior Pediatrician, Department of Paediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand
  • Ploenchan Chetchotisakd MD, Professor of Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Thailand
  • Pope Kosalaraksa, MD, Associate Professor of Paediatrics, Department of Paediatrics, Faculty of Medicine, Khon Kaen University, Thailand
  • Pranee Moungnoi MD, Consultant Psychiatrist, Department of Child and Adolescent Psychiatry, Institute of Child Health, Thailand
  • Manop Srisuphanthavorn MD, Chief Medical Officer, Bangkwang Central Prison, Thailand
  • Witaya Petdachai MD, Hospital Deputy Director and Head of Paediatrics, Phrachomklao Hospital, Thailand
  • Chureeratna Bowon MD, Senior Physician, Chonburi Regional Hospital, Thailand
  • Jon Ungphakorn, Senator and member of Public Health Committee, The Senate, Parliament House, Thailand
  • Sureerat Thimakkra, Representative, National Economic and Social Advisory Council, Thailand
  • Vithaya Kulsomboon PhD, MPHM, Chair of Social Pharmacy Department , Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
  • Niyada Kiatying-Angsulee, Ph.D, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
  • Jiraporn Limpananont, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
  • Sumlee Jaidee, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
  • Kamon Uppakaew, Chairman, Thai Network for People With HIV/AIDS, Thailand
  • Nimit Tienudom, Director, AIDS Access Foundation, Thailand
  • Paisan Suwannawong, Director, Thai AIDS Treatment Action Group (TTAG), Thailand
  • Karyn Kaplan, Director, Policy and Development, Thai AIDS Treatment Action Group (TTAG), Thailand
  • Christian Aid, United Kingdom
  • International Planned Parenthood Federation, United Kingdom
  • DHIVERSE, United Kingdom
  • The UWESO UK Trust (Uganda Women's Effort to Save Orphans), United Kingdom
  • National AIDS Trust, United Kingdom
  • International HIV/AIDS Alliance, United Kingdom
  • UK Coalition of People Living with HIV and AIDS, United Kingdom
  • Dr. Ed Wilkins, Specialist in HIV/AIDS and WHO Consultant, North Manchester Hospital, United Kingdom
  • Fiona Pettitt, International Community of Women living with HIV/AIDS (ICW), London, United Kingdom
  • ACCSI - Acción Ciudadana Contra el SIDA, Venezuela